| Date | Title | Description |
| 13.09.2024 | New Frontiers in Cancer Imaging and Treatment: A Look at SECuRE and ZIRCON Trials | In the ever-evolving landscape of cancer treatment, two recent trials have emerged as beacons of hope. The SECuRE trial and the ZIRCON trial are paving the way for innovative therapies and diagnostic tools that could redefine patient care. ... |
| 11.09.2024 | 'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology | MELBOURNE, Australia, Sept. 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON[1] trial have been published in The Lancet Oncology, reporting ... |
| 05.09.2024 | Promising Advances in Cancer Treatment: A Look at TiNivo-2 and TLX101 | In the ever-evolving landscape of cancer treatment, two recent studies stand out like beacons of hope. The TiNivo-2 trial by AVEO Oncology and the IPAX-1 study by Telix Pharmaceuticals both unveil new possibilities for patients battling agg... |
| 04.09.2024 | IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances | MELBOURNE, Australia, Sept. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety an... |
| 29.08.2024 | Telix Pharmaceuticals: A Rising Star in Precision Oncology | Telix Pharmaceuticals is on a roll. The Australian biopharmaceutical company is making waves in the world of precision oncology. With its recent half-year results and a strategic reorganization, Telix is positioning itself as a leader in th... |
| 28.08.2024 | Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent | MELBOURNE, Australia, Aug. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) fo... |
| 27.08.2024 | Telix Announces Reorganisation to Deliver on Strategic Priorities | MELBOURNE, Australia, Aug. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to align its operations across four business ... |
| 22.08.2024 | Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities | MELBOURNE, Australia, Aug. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise stated.[1]
... |
| 26.07.2024 | Telix Pharmaceuticals: A Bold Step into the Future with Convertible Bonds**
** | ** In the world of biopharmaceuticals, Telix Pharmaceuticals Limited is making waves. The Melbourne-based company recently announced the successful pricing of A$650 million in convertible bonds. This move is not just a financial maneuver; i... |
| 24.07.2024 | Telix Successfully Prices A$650 Million Convertible Bonds | MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully priced A$650 million 2.375 per cent convertible notes due 2029. Th... |
| 24.07.2024 | FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent | MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Applic... |
| 23.07.2024 | Telix Announces A$600 Million Convertible Bonds Offering | MELBOURNE, Australia, July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering of A$600 million of convertible notes due 2029 (the Offering). The convertible notes, a... |
| 18.07.2024 | Telix Pharmaceuticals Q2 2024 Revenue and Business Highlights, Guidance Upgrade | MELBOURNE, Australia, July 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 June 2024 (Q2 2024).
Q2 2024 Finan... |
| 11.07.2024 | Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals | MELBOURNE, Australia, July 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes proposed changes announced by the Centers for Medicare & Medicaid Services (CMS) for the Hospital Outpatient... |
| 03.06.2024 | Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging | MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food a... |
| 31.05.2024 | Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer | TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.
Reported median radiographic progression-free survival (rP... |
| 27.05.2024 | Telix Submits NDA for New Prostate Cancer Imaging Agent | MELBOURNE, Australia, May 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for... |
| 21.05.2024 | Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer | CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.
Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently... |
| 17.04.2024 | Q1 2024 Revenue and Business Update | MELBOURNE, Australia, April 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024).
Summary: Q1... |
| 16.04.2024 | TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation | FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging
Collaboration agreement announced for joint development and commercialisation with UCSF
PharmaLogic announced as commercial manufacturing and pharmacy distr... |
| 27.03.2024 | World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain | LONDON, March 27, 2024 /PRNewswire/ -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure w... |
| 19.03.2024 | QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy | MELBOURNE, Australia and DRESDEN, Germany, March 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement to commercially partner the QDOSE® dosimetry softwa... |
| 12.03.2024 | Appointment of Dr Darren Patti to Group Chief Operating Officer | MELBOURNE, Australia, March 12, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024.
Dr... |
| 11.03.2024 | Appointment of Dr Darren Patti to Group Chief Operating Officer | MELBOURNE, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024... |
| 08.03.2024 | Telix Expands Reach with Acquisition of ARTMS, Inc. | Telix Pharmaceuticals Limited has made a bold move by acquiring ARTMS Inc., a leader in radioisotope production technology. This strategic acquisition will enhance Telix's supply chain and manufacturing capabilities, giving them greater con... |
| 05.03.2024 | Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform | MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its adv... |
| 04.03.2024 | Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform | MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), it... |
| 27.02.2024 | Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics | MELBOURNE, Australia, Feb. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiophar... |
| 22.02.2024 | Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline | MELBOURNE, Australia, Feb. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the financial year ended 31 December 2023. All figures are in AUD$ unless otherwise stated.[1]
... |
| 08.02.2024 | Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform | MELBOURNE, Australia , Feb. 8, 2024 /PRNewswire/ --.Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigationa... |
| 22.01.2024 | Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024) | MELBOURNE, Australia, Jan. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company's theranostic programs at the upcoming American Society of Clinical Oncolog... |
| 04.01.2024 | Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference | MELBOURNE, Australia, Jan. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 42nd Annual J.P. Morgan ... |
| 19.12.2023 | Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer | MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food... |
| 11.12.2023 | First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent | MELBOURNE, Australia and INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a United States (U.S.) expanded access program (EAP, ... |
| 07.12.2023 | Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS | MELBOURNE, Australia, Dec. 7, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces positive topline results from the Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX... |
| 04.12.2023 | First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent | MELBOURNE, Australia and LIÉGE, Belgium, Dec. 4, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a named patient (early access) program in the Nether... |
| 30.11.2023 | Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS | MELBOURNE, Australia, Nov. 30, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-ta... |
| 14.11.2023 | Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam® | MELBOURNE, Australia, Nov. 14, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM) and its lead asset, CycloSam® (... |
| 13.11.2023 | Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery | MELBOURNE, Australia and PARIS, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Paris-based Mauna Kea Technologies (Euronext Growth: ALMKT, Mauna Kea), today announce an expansion of the IRiS (... |
| 13.11.2023 | First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591 | MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company's Phase III ProstACT GLOBAL study of its investigational p... |
| 09.11.2023 | Telix to Present at Jefferies London Healthcare Conference 2023 | MELBOURNE, Australia, Nov. 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies London Healthc... |
| 08.11.2023 | Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region | MELBOURNE, Australia, Nov. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement with Denmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Te... |
| 19.10.2023 | ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability | The study has achieved its primary objectives, confirming the safety and tolerability profile of TLX591 administered in two doses, two weeks apart in combination with standard of care (SoC)
Preliminary activity demonstrates meaningful PSA[1... |
| 18.10.2023 | Telix reports fourth consecutive quarter of positive operating cash flow | MELBOURNE, Australia, Oct. 18, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 September 2... |
| 27.09.2023 | HRH Princess Astrid of Belgium visits Telix's New European Manufacturing Facility in Brussels South | MELBOURNE, Australia and LIEGE, Belgium, Sept. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has welcomed Her Royal Highness, Princess Astrid, Princess of Belgium to Telix Manufacturing Solutions (TMS... |
| 06.09.2023 | Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM | MELBOURNE, Australia, Sept. 6, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company's theranostic programs at the 36th Annual Congress of the European Associat... |
| 23.08.2023 | Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company | MELBOURNE, Australia, Aug. 23, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2023. All figures are in AUD$ unless otherwise stated.[1]... |
| 11.08.2023 | First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients | MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illucci... |
| 08.08.2023 | First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma | MELBOURNE, Australia, Aug. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase I study of the Company's investigational therapy TLX101 (4-L-[131... |
| 19.07.2023 | Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow | MELBOURNE, Australia, July 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 June 2023 (... |
| 19.07.2023 | First Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib | MELBOURNE, Australia, July 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Company's investigational targeted radiation th... |
| 27.06.2023 | New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC | MELBOURNE, Australia, June 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-D... |
| 22.06.2023 | Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI | MELBOURNE, Australia, June 22, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company's investigational prostate (prostate specific-membrane antigen, or PSMA-targetin... |
| 21.06.2023 | Telix Urology Innovation Showcase to be held at The Yale Club, New York City | MELBOURNE, Australia and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an outline agenda for the Company's briefing session for shareholders to be held on Wednesday, ... |
| 21.06.2023 | Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical | MELBOURNE, Australia, June 21, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. L... |
| 19.06.2023 | First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion | MELBOURNE, Australia, June 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II study of the Company's carbonic anhydrase- (CAIX)-targeting... |
| 15.06.2023 | Telix Briefing: Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer | June 21, 2023, at The Yale Club, New York City
Featured speakers and Key Opinion Leaders include: Dr Christian Behrenbruch, Dr Colin Hayward, Kevin Richardson, Dr Brian Shuch and Dr Scott Tagawa
Topics include Telix's urologic pipeline, dev... |
| 08.06.2023 | Telix Opens European Radiopharmaceutical Production Facility | Telix has unveiled its new, state-of-art radiopharmaceutical facility in Brussels South as part of its first stage investment of €14.1 million ($A21.2 million)
Located in Walloon's 'Radiopharma Valley' the facility will be a central hub for... |
| 06.06.2023 | Telix to Present at Jefferies Healthcare Conference | MELBOURNE, Australia, June 6, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Con... |
| 25.05.2023 | Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology | June 21, 2023, at The Yale Club, New York City
The Company will showcase its urologic pipeline, development of novel therapeutics, imaging agents and technologies that aim to harness the power of targeted radiation at every step of the pati... |
| 08.05.2023 | Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites | MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit... |
| 08.05.2023 | Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study | MELBOURNE, Australia, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparat... |
| 07.05.2023 | Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study | MELBOURNE, Australia, May 7, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited TLX Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of ... |
| 02.05.2023 | First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide | MELBOURNE, Australia, May 2, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illuccix... |
| 01.05.2023 | ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller | MELBOURNE, Australia, May 1, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuxima... |
| 01.05.2023 | First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide | MELBOURNE, Australia, May 1, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited TLX Telix, the Company) today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illuccix® [kit ... |
| 27.04.2023 | Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid | MELBOURNE, Australia, April 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the expansion of its artificial intelligence (AI) capability with the signing of an agreement to acquire Vienn... |
| 17.04.2023 | Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical | MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Compan... |
| 17.04.2023 | Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter | MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March 2... |
| 11.04.2023 | Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate | MELBOURNE, Australia, April 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a Ph... |
| 16.03.2023 | FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy | MELBOURNE, Australia, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (s... |
| 16.03.2023 | FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy | INDIANAPOLIS, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for... |
| 14.03.2023 | Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU | MELBOURNE, Australia, March 14, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentux... |
| 09.03.2023 | Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU | MELBOURNE, Australia, March 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company's carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at t... |
| 27.02.2023 | Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive | MELBOURNE, Australia, Feb. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the financial year ended 31 December 2022. All figures are in AU$ unless otherwise st... |
| 20.02.2023 | Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU | Trial met primary and secondary endpoints and confirmed favourable safety and tolerability profile, indicating TLX250-CDx has the potential to become a new clinical standard in the identification and characterisation of clear cell renal cel... |
| 15.02.2023 | Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine | MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) un... |
| 18.01.2023 | Telix Reports Fourth Quarter 2022 Financial Results | MELBOURNE, Australia, Jan. 18, 2023 /PRNewswire/ -- 18 January 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ... |
| 09.01.2023 | Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update | MELBOURNE, Australia, Jan. 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9 – 12 January) in San Francisco.
As part o... |
| 09.01.2023 | Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update | MELBOURNE, Australia, Jan. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited TLX Telix, the Company) today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9 – 12 January) in San Francisco.
As part of the C... |
| 22.12.2022 | ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances | Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will be presented at American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Sym... |
| 05.12.2022 | Telix Announces Executive Leadership Appointments | MELBOURNE, Australia, Dec. 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the C... |
| 22.11.2022 | First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy | MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with ex... |
| 22.11.2022 | Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand | INDIANAPOLIS, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is availab... |
| 14.11.2022 | Telix Acquires Optimal Tracers | MELBOURNE, Australia and INDIANAPOLIS, Ind., Nov. 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Sacramento-based Northern California PET Imag... |
| 14.11.2022 | Telix Pharmaceuticals Acquires Optimal Tracers | Telix Pharmaceuticals a Melbourne, Australia-based biopharmaceutical company, acquired Optimal Tracers, an Indianapolis, IN-based radiochemistry development company.
The amount of the deal was not disclosed.
With the acquisition, Telix Phar... |
| 11.11.2022 | Telix to Present at Jefferies London Healthcare Conference 2022 | MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic ra... |
| 07.11.2022 | Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study | Summary of Study Outcomes
ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary endpoints
The study delivered co-primary endpoints of 8... |
| 27.10.2022 | Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide | MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of The University of Queensland... |
| 27.10.2022 | Telix Recognised as Company of the Year at AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2022 | MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is today pleased to announce that it has been awarded Australian Company of the Year in the 2022 AusBiotech and Johnson & J... |
| 20.10.2022 | Telix Reports Third Quarter 2022 Financial Results | MELBOURNE, Australia, Oct. 20, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 Septembe... |
| 18.10.2022 | TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM | OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast cancer – early results suggest potential to detect carbonic anhydrase IX (CAIX) expression, theranostic potential in this difficult to treat diseas... |
| 17.10.2022 | Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging | MELBOURNE, Australia, Oct. 17, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved ... |
| 17.10.2022 | Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market | New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare's immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trials
Telix tracers evaluate levels of carbonic anhydrase IX ... |
| 16.10.2022 | Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging | MELBOURNE, Australia, Oct. 16, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited TLX Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an inve... |
| 14.10.2022 | Health Canada Approves Illuccix® for Prostate Cancer Imaging | MELBOURNE, Australia, Oct. 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that Health Canada has approved Illuccix® [kit for the preparation of gallium (68Ga) gozetotide injection] for use in... |
| 14.10.2022 | Health Canada Approves Illuccix® for Prostate Cancer Imaging | MELBOURNE, Australia, Oct. 13, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited TLX Telix, the Company) announces that Health Canada has approved Illuccix® [kit for the preparation of gallium (68Ga) gozetotide injection] for use in stagin... |
| 30.09.2022 | First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent | MELBOURNE, Australia, Sept. 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the first commercial dose in New Zealand of its prostate cancer imaging agent, Illuccix® (Kit for Preparation ... |
| 28.09.2022 | First Patient in Australia Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent | MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the first commercial dose in Australia of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of... |
| 28.09.2022 | Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate | MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved... |
